Income Statement (Annual)

ORGS / Orgenesis, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Revenues 0 0 - - 0 2,974 6,397 10,089
Cost Of Revenue - - - - 0 3,880 7,657 6,807
Gross Profit - - - - 0 -906 -1,260 3,282
Research And Development Expense - 0 2,309 1,452 1,549 1,067 2,157 2,478
Amortization Of Intangible Assets - - - - 0 1,203 1,620 1,631
General And Administrative Expense 3 1 2,680 4,008 3,027 4,035 6,240 9,189
Other Operating Income - - - - - - - -
Operating Income Loss - - - - -4,577 -7,211 -11,400 -11,230
Other Nonoperating Income Expense - 0 -10 -79 -927 1,850 -1,260 -2,447
Income Loss From Equity Method Investments - - - - - - - -
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments -36 -72 -4,989 -5,461 -4,577 -5,361 -12,660 -13,677
Income Tax Expense Benefit 0 0 - - 0 -900 -1,547 -1,310
Profit Loss -36 -72 - - - - - -
Net Income Loss Attributable To Redeemable Noncontrolling Interest - - - - - - - -
Earnings Per Share
  Earnings Per Share Basic - - - 0 0 0 0 0
  Earnings Per Share Diluted - - - 0 0 0 0 0
Weighted Average Number Of Shares Outstanding Basic
  Weighted Average Number Of Shares Outstanding Basic - - - 50,484 54,163 55,798 8,522 9,680
  Weighted Average Number Of Diluted Shares Outstanding - 80,500 54,265 50,484 54,722 56,921 8,522 9,714
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
  Net Income Loss -36 -72 -4,998 -5,539 -5,504 -4,461 -11,113 -12,367
  Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent - - - 0 -18 -1,268 81 2,630
Comprehensive Income Net Of Tax - -72 -4,998 -5,539 -5,522 -5,729 -11,032 -9,737

Peers - Pharmaceutical Preparations (2834)

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 68619K105